A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns

Wound Repair Regen. 2009 Sep-Oct;17(5):685-9. doi: 10.1111/j.1524-475X.2009.00526.x.

Abstract

Wound healing is a complex and dynamic biological process. The efficacy and safety of a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) hydrogel to promote deep-second-degree burn wound healing is evaluated in this study. In this multicenter, randomized, double-blind, and placebo-controlled clinical trial, 90 patients with deep second-degree burns were randomly assigned into two groups. Complete healing time and percentage of wound healing at different time points were observed and side effects were recorded. A statistically significant difference was noted at each time point (p<0.01). No side effects were observed. These results suggest that rhGM-CSF hydrogel can significantly accelerate deep second-degree burn wound healing and is considered to be safe.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Burns / drug therapy*
  • Burns / therapy
  • Dermatologic Agents / administration & dosage*
  • Double-Blind Method
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Humans
  • Hydrogel, Polyethylene Glycol Dimethacrylate / administration & dosage*
  • Male
  • Recombinant Proteins
  • Treatment Outcome
  • Wound Healing / drug effects*

Substances

  • Dermatologic Agents
  • Recombinant Proteins
  • Hydrogel, Polyethylene Glycol Dimethacrylate
  • Granulocyte-Macrophage Colony-Stimulating Factor